Flameng W - Search Results

1

Coronary thrombolysis and infarct size reduction after intravenous infusion of recombinant tissue-type plasminogen activator in nonhuman primates.

Flameng W, Van de Werf F, Vanhaecke J, Verstraete M, Collen D. Flameng W, et al. J Clin Invest. 1985 Jan;75(1):84-90. doi: 10.1172/JCI111701. J Clin Invest. 1985. PMID: 4038406 Free PMC article.

2

Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.

Flameng W, Vanhaecke J, Stump DC, Van de Werf F, Holmes W, Guenzler WA, Flohe L, Collen D. Flameng W, et al. J Am Coll Cardiol. 1986 Jul;8(1):118-24. doi: 10.1016/s0735-1097(86)80101-2. J Am Coll Cardiol. 1986. PMID: 3086416 Free article.

3

Determinants of infarct size in non-human primates.

Flameng W, Lesaffre E, Vanhaecke J. Flameng W, et al. Basic Res Cardiol. 1990 Jul-Aug;85(4):392-403. doi: 10.1007/BF01907131. Basic Res Cardiol. 1990. PMID: 2241769

4

Limitation of experimental infarct size by drugs.

Flameng W, Vanhaecke J, Lesaffre E. Flameng W, et al. J Cardiovasc Pharmacol. 1989;14 Suppl 9:S29-33. J Cardiovasc Pharmacol. 1989. PMID: 2483229

5

Reduction in infarct size and enhanced recovery of systolic function after coronary thrombolysis with tissue-type plasminogen activator combined with beta-adrenergic blockade with metoprolol.

Van de Werf F, Vanhaecke J, Jang IK, Flameng W, Collen D, De Geest H. Van de Werf F, et al. Among authors: flameng w. Circulation. 1987 Apr;75(4):830-6. doi: 10.1161/01.cir.75.4.830. Circulation. 1987. PMID: 3103951

6

Studies on experimental myocardial infarction: dogs or baboons?

Flameng W, Vanhaecke J, Vandeplassche G. Flameng W, et al. Cardiovasc Res. 1986 Apr;20(4):241-7. doi: 10.1093/cvr/20.4.241. Cardiovasc Res. 1986. PMID: 3719603

7

Intravenous metoprolol preceding thrombolysis in acute thrombotic myocardial infarction in the dog; effects on infarct size, myocardial blood flow, and left ventricular function.

Zmudka K, Dubiel J, Vanhaecke J, Flameng W, De Geest H. Zmudka K, et al. Among authors: flameng w. J Cardiovasc Pharmacol. 1994 Jul;24(1):78-86. doi: 10.1097/00005344-199407000-00014. J Cardiovasc Pharmacol. 1994. PMID: 7521494

8

Effects of oral pretreatment with metoprolol on left ventricular wall motion, infarct size, hemodynamics, and regional myocardial blood flow in anesthetized dogs during thrombotic coronary artery occlusion and reperfusion.

Zmudka K, Dubiel J, Vanhaecke J, Flameng W, De Geest H. Zmudka K, et al. Among authors: flameng w. Cardiovasc Drugs Ther. 1994 Jun;8(3):479-87. doi: 10.1007/BF00877926. Cardiovasc Drugs Ther. 1994. PMID: 7947365

9

Early intravenous administration of metoprolol enhances myocardial salvage by thrombolysis with recombinant tissue-type plasminogen activator after thrombotic coronary artery occlusion in the dog by improvement of the collateral blood flow to the area at risk.

Zmudka K, Aubert A, Dubiel J, Vanhaecke J, Flameng W, Kaczmarek J, De Geest H. Zmudka K, et al. Among authors: flameng w. J Am Coll Cardiol. 1994 May;23(6):1499-504. doi: 10.1016/0735-1097(94)90398-0. J Am Coll Cardiol. 1994. PMID: 8176113 Free article.

10

Effect of superoxide dismutase on infarct size and postischemic recovery of myocardial contractility and metabolism in dogs.

Vanhaecke J, Van de Werf F, Ronaszeki A, Flameng W, Lesaffre E, De Geest H. Vanhaecke J, et al. Among authors: flameng w. J Am Coll Cardiol. 1991 Jul;18(1):224-30. doi: 10.1016/s0735-1097(10)80243-8. J Am Coll Cardiol. 1991. PMID: 2050925 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

403 results

Search Page